Beijing, June 4 (China News Service) – Concerns have been raised regarding the circulation of an anti-cancer drug, produced by Akeso Inc. (康方生物), labeled For Clinical Research Use Only, to patients.
The issue came to light following reports that a cervical cancer patient, identified as Ms. Li, experienced adverse reactions, specifically pneumonia, after being administered Cadonilimab injections. The treatment was reportedly recommended by Dr. Li, a physician at the Chongqing University Cancer Hospital. Subsequently, Ms. Li discovered that the Cadonilimab injections she had purchased were explicitly marked For Clinical Research Use Only.
The incident has sparked debate about the regulatory oversight of clinical trial drugs and the potential risks to patients receiving medication outside of a controlled research environment. Akeso Inc. has yet to release a detailed statement addressing the specific allegations, but the company has acknowledged the reports and stated that they are conducting an internal investigation.
This is a developing story, and China News Service will continue to provide updates as more information becomes available. The focus remains on patient safety and ensuring the integrity of the drug development and distribution process.
Views: 0